LifeVantage (NASDAQ:LFVN) is scheduled to announce its earnings results after the market closes on Thursday, November 1st.
LifeVantage (NASDAQ:LFVN) last posted its quarterly earnings data on Wednesday, August 15th. The company reported $0.20 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.17 by $0.03. The company had revenue of $54.03 million during the quarter. LifeVantage had a return on equity of 39.14% and a net margin of 2.84%.
NASDAQ:LFVN opened at $11.33 on Wednesday. The firm has a market cap of $153.19 million, a P/E ratio of 22.22 and a beta of 0.87. LifeVantage has a 52-week low of $3.20 and a 52-week high of $13.29. The company has a debt-to-equity ratio of 0.16, a current ratio of 1.64 and a quick ratio of 1.06.
LifeVantage Corporation engages in the identification, research, development, and distribution of nutraceutical dietary supplements and skin care products. The company offers Protandim, a scientifically-validated dietary supplement; LifeVantage TrueScience, an anti-aging skin care product; Axio, a line of energy drink mixes; Omega+, a fish oil dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and Vitamin D3; and PhysIQ, a weight management system, as well as Petandim for Dogs, a companion pet supplement formulated to treat oxidative stress in dogs.
Receive News & Ratings for LifeVantage Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifeVantage and related companies with MarketBeat.com's FREE daily email newsletter.